Description: Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Home Page: www.armatapharma.com
5005 McConnell Avenue
Los Angeles,
CA
90066
United States
Phone:
310 665 2928
Officers
| Name | Title |
|---|---|
| Dr. Deborah L. Birx M.D. | CEO & Director |
| Dr. Mina Pastagia M.D., MS | Chief Medical Officer |
| Mr. David House | Senior VP of Finance & Principal Financial Officer |
| Mr. Peter Hubbard | Vice President of Operations |
| Dr. Pierre Kyme Ph.D. | Chief Business Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.4365 |
| Price-to-Sales TTM: | 20.0841 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 66 |